Medical cost affordability dominated the midterm election cycle, driven by Kaiser Family Foundation statistics indicating that 62% of adults experience anxiety regarding their ability to finance medical services for their households.

While candidates across the political spectrum heavily promoted various forms of financial relief during their campaigns, the newly sworn-in lawmakers are now confronting the stark divergence between political rhetoric and legislative execution.

Why Popular Healthcare Solutions Fall Short

Throughout the campaign trail, progressive Democrats heavily promoted the Medicare for All framework. Michigan Senate contender Abdul El-Sayed championed substituting private insurance with a completely government-backed model, a concept that KFF polling shows commands backing from two-thirds of American adults.

Nevertheless, broadening health coverage through Medicare for All fails to inherently streamline or optimize the delivery of medical services.

At present, federal statute empowers the Centers for Medicare and Medicaid Services to dictate Medicare reimbursement rates independently, without engaging in direct negotiations with medical practitioners or healthcare institutions. Furthermore, Congress restricts how rapidly these reimbursement schedules can increase. To comply with these statutory ceilings, current Medicare payouts trail reported hospital operating expenses by roughly 10%. RAND data indicates that hospitals offset these federal shortfalls by billing private insurance providers an average of 254% of standard Medicare rates.

Should the entire American populace have their healthcare expenses compensated strictly at Medicare rates, hospital revenues would collapse drastically while consumer demand for medical services remained unchanged. Given that 43% of hospitals currently operate in a deficit, these medical centers would face inevitable closures or severe reductions in service capacity.

Conservatives characteristically lean toward minimized government interference, yet several prominent figures—including Senator Susan Collins of Maine—have actively advocated for price restrictions. Most recently, she spearheaded bipartisan legislation designed to cap monthly out-of-pocket insulin expenses at $35 for individuals with private insurance.

Historically, spending and price ceilings have yielded mixed outcomes, consistently failing to resolve the fundamental structural flaws plaguing healthcare delivery. Past attempts to cap provider reimbursement merely triggered spikes in the volume of services rendered as physicians scrambled to preserve their revenue streams. Similarly, placing blanket caps on total healthcare spending without simultaneously driving efficiency invariably generates severe bottlenecks, forcing patients to endure extended waiting lists for nonurgent procedures, a phenomenon clearly visible in nations like the United Kingdom and Canada.

Two Ways To Improve The Economics

Aggregate U.S. healthcare expenditures have escalated to $5.7 trillion annually, eclipsing the total gross domestic product of nations such as Germany or Japan. By 2026, employer-sponsored family health insurance premiums surged by 5%, significantly outpacing the 2.7% inflation rate and the 3.7% wage growth.

Addressing a crisis of this monumental scale precludes simplistic, short-term fixes. Genuine, lasting progress demands deliberate legislative intervention centered around two highly promising strategic directions. The first focuses on proactively elevating public health to suppress costly, preventable medical complications, while the second aims to stimulate robust market competition that compels insurers and medical providers to elevate care quality while reducing expenses.

1. Reducing Costs By Improving Health

The principal drivers of life-threatening and exceptionally expensive inpatient hospitalizations stem from complications associated with chronic conditions and obesity. Collectively, these maladies trigger millions of preventable strokes, heart attacks, kidney failures, and cancer diagnoses every year.

Successfully preventing chronic illnesses or achieving tighter management once they manifest could shave hundreds of billions of dollars off expensive medical treatments. Two recent technological and pharmaceutical breakthroughs present unprecedented opportunities.

Affordable GLP-1 medications

Following decades characterized by largely disappointing weight-loss interventions, modern pharmacological therapies have delivered remarkable outcomes. Major clinical trials demonstrate that treatments utilizing semaglutide and tirzepatide achieve average weight reductions ranging from approximately 15% to 21%, contingent on the specific drug and dosage administered.

However, steep price points severely restrict access to GLP-1 medications. To widen availability for the 40% of Americans classified as obese, Congress could amend the Food, Drug, and Cosmetic Act to authorize lower-cost compounded alternatives whenever FDA-approved medications remain financially out of reach. This legislative adjustment would expand established drug-shortage exemptions to encompass treatments that are economically inaccessible, even in environments where physical supply chains remain stable.

Generative AI for chronic disease control

While prevention remains paramount, tens of millions of citizens will inevitably contract chronic illnesses. Centers for Disease Control and Prevention data reveals that fewer than half of Americans diagnosed with diabetes or hypertension successfully maintain their blood glucose or blood pressure within recommended parameters. Implementing more frequent health tracking and timely medication adjustments would drastically improve disease management.

Deploying a patient-facing generative AI architecture linked directly to residential blood glucose meters or blood pressure cuffs would empower continuous data monitoring, instantly flag inadequate responses to ongoing treatments, and notify clinical staff. Physicians could subsequently recalibrate medication dosages months ahead of scheduled routine appointments, thereby tightening disease control and drastically lowering the incidence of expensive health complications like kidney failure, strokes, and cardiac events.

To deliver this advanced level of clinical assistance universally, Congress and the executive branch should establish an Operation Warp Speed-style task force uniting the National Institutes of Health, the FDA, CMS, artificial intelligence innovators, and practicing clinicians. This collaborative coalition would construct, thoroughly validate, implement, and continuously oversee these affordable patient tools to ensure optimal clinical efficacy, reliability, and safety.

2. Lowering Costs Through Greater Competition And Improved Care

Roughly 166 million Americans secure health coverage via their employers, frequently bound by severely restricted plan selections. The federal government possesses the mechanism to broaden marketplace competition through an existing federal framework.

Introduced in 2020, Individual Coverage Health Reimbursement Arrangements (ICHRAs) empower employers to allocate defined financial contributions while enabling workers to select the optimal insurance plans for their households, including options available on ACA health insurance exchanges. This pathway grants businesses superior cost predictability while eliminating the administrative burden of selecting specific insurance packages for staff.

Congress could significantly optimize this program through two primary statutory adjustments.

First, lawmakers should grant workers greater financial flexibility. For instance, if a household receives a $20,000 employer subsidy and opts for a qualifying health plan priced at $15,000, new legislation could permit the remaining $5,000 balance—subject to statutory limits—to be deposited directly into an employee-owned, tax-advantaged Health Savings Account.

Second, federal rules should mandate the public disclosure of independently verified metrics detailing premiums, out-of-pocket financial exposure, clinical performance outcomes, and network accessibility, thereby enabling households to rigorously evaluate the overall value proposition across competing plans.

Drawing a larger volume of working-class Americans into individual insurance marketplaces will naturally attract a greater number of insurance carriers and intensify market competition. Regional health plans could forge strategic alliances with local hospital networks or capitated physician groups to curate economical insurance products centered on coordinated care delivery and superior health outcomes.

Heightened market rivalry would naturally compel insurance providers to negotiate lower service rates while financially rewarding high-performing, efficient medical providers. Although local market dynamics will dictate localized variations, these systemic financial incentives would stimulate widespread industry innovation and elevate overall healthcare value nationwide.

Implementing targeted initiatives to elevate public health alongside structural reforms designed to foster market competition will collectively drive down medical expenses. Once the political campaigns fade, Congress must transcend empty promises and execute concrete measures to restore affordability to the American healthcare system.